Tonix Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $7.9M

Website

Clinical Trials

Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache

Phase 2

Completed

Conditions: Tension-Type Headache

Interventions: Drug: TNX-201
Drug: Placebo

First Posted Date: 2015-04-22

Last Posted Date: 2017-04-11

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 165

Registration Number: NCT02423408

Locations: 🇺🇸
Rapid Medical Research, Inc., Cleveland, Ohio, United States
🇺🇸
Avail Clinical Research LLC., DeLand, Florida, United States
🇺🇸
Duane G. Wombolt, MD, Norfolk, Virginia, United States

and more 7 locations

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

Phase 2

Completed

Conditions: PTSD

Interventions: Drug: TNX-102 SL

First Posted Date: 2015-04-21

Last Posted Date: 2017-10-31

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 159

Registration Number: NCT02421679

Locations: 🇺🇸
CITRIALS, Riverside, California, United States
🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
Cns, Inc., Torrance, California, United States

and more 19 locations

Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TNX-201 35 mg
Drug: TNX-201 70 mg
Drug: TNX-201 140 mg
Drug: Placebo
Drug: Racemic isometheptene 70 mg

First Posted Date: 2014-11-14

Last Posted Date: 2016-05-17

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 27

Registration Number: NCT02290379

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

Phase 2

Completed

Conditions: PTSD

Interventions: Drug: Placebo
Drug: TNX-102 SL

First Posted Date: 2014-10-29

Last Posted Date: 2024-06-20

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 245

Registration Number: NCT02277704

Locations: 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
Altea Research, Las Vegas, Nevada, United States
🇺🇸
Cincinnati, Cincinnati, Ohio, United States

and more 20 locations

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients

Phase 3

Completed

Conditions: Primary Fibromyalgia

Interventions: Drug: TNX-102 SL

First Posted Date: 2013-12-19

Last Posted Date: 2017-07-07

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 158

Registration Number: NCT02015234

Locations: 🇺🇸
71 Thomas Johnson Drive, Frederick, Maryland, United States
🇺🇸
370 Faunce Corner Road, North Dartmouth, Massachusetts, United States
🇺🇸
Jackson, Jackson, Mississippi, United States

and more 10 locations

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

Phase 2

Completed

Conditions: Primary Fibromyalgia

Interventions: Drug: TNX-102 SL 2.8mg
Drug: Placebo

First Posted Date: 2013-07-19

Last Posted Date: 2016-12-23

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 205

Registration Number: NCT01903265

Locations: 🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸
CRC of Jackson, LLC, Jackson, Mississippi, United States
🇺🇸
1275 Olentangy River Road, Columbus, Ohio, United States

and more 14 locations

Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: TNX-102 SL Tablets at 2.8 mg
Drug: Cyclobenzaprine tablets
Drug: TNX-102-B SL Tablets at 2.8 mg
Drug: TNX-102-C SL Tablets at 2.8 mg

First Posted Date: 2013-06-28

Last Posted Date: 2014-09-26

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT01889173

Locations: 🇨🇦
PharmaNet, Inc., Quebec City, Quebec, Canada

Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: SL TNX-102-A at 2.4 mg
Drug: Cyclobenzaprine tablets
Drug: SL TNX-102 at 2.4 mg
Drug: SL TNX-102 at 4.8 mg

First Posted Date: 2012-09-21

Last Posted Date: 2014-09-26

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT01689259

Locations: 🇨🇦
PharmaNet, Inc., Quebec City, Quebec, Canada

Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: Cyclobenzaprine IV
Drug: SL TNX-102 2.4 mg at pH 3.5
Drug: SL TNX-102 2.4 mg at pH 7.1
Drug: Cyclobenzaprine Tablet

First Posted Date: 2012-07-06

Last Posted Date: 2014-09-26

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT01634412

Locations: 🇨🇦
PharmaNet, Inc., Quebec City, Quebec, Canada

A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C

First Posted Date: 2011-12-13

Last Posted Date: 2019-09-11

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT01490788

Locations: 🇨🇦
PharmaNet, Inc., Québec City, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy